argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
| Index | Market Cap | Enterprise Value | Income | Sales | Book/sh | Cash/sh | Dividend Est. | Dividend TTM | Dividend Ex-Date | Dividend Gr. 3/5Y | Payout | Employees | IPO |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 61.80B | 56.66B | 1.71B | 5.22B | 136.01 | 82.86 | - | - | - | - - | 0.00% | 1863 | May 18, 2017 |